{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:38:16Z","timestamp":1792733896167,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-026-02410-1","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:51:02Z","timestamp":1792731062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zidesamtinib: First Approval"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-7391","authenticated-orcid":false,"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"11","key":"2410_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/oncolo\/oyae205","volume":"29","author":"MC Boulanger","year":"2024","unstructured":"Boulanger MC, Schneider JL, Lin JJ. Advances and future directions in ROS1 fusion-positive lung cancer. Oncologist. 2024;29(11):943\u201356.","journal-title":"Oncologist"},{"issue":"1","key":"2410_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","volume":"18","author":"A Drilon","year":"2021","unstructured":"Drilon A, Jenkins C, Iyer S, et al. ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"2410_CR3","unstructured":"Riely GJ, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 4.2026, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2026;24(4):e260017."},{"key":"2410_CR4","unstructured":"GSK. Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer [media release]. 22 July 2026. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/jideytro-zidesamtinib-approved-in-the-us-for-previously-treated-ros1-positive-non-small-cell-lung-cancer\/."},{"issue":"7","key":"2410_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1158\/1535-7163.MCT-25-0025","volume":"24","author":"A Tangpeerachaikul","year":"2025","unstructured":"Tangpeerachaikul A, Mente S, Magrino J, et al. Zidesamtinib selective targeting of diverse ROS1 drug-resistant mutations. Mol Cancer Ther. 2025;24(7):1005\u201319.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2410_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-22-0968","volume":"13","author":"A Drilon","year":"2023","unstructured":"Drilon A, Horan JC, Tangpeerachaikul A, et al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discov. 2023;13(3):598\u2013615.","journal-title":"Cancer Discov"},{"key":"2410_CR7","unstructured":"US FDA. FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer. 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer. Accessed 02 Oct 2026."},{"key":"2410_CR8","unstructured":"US FDA. JIDEYTROTM (zidesamtinib) tablets, for oral use: US prescribing information. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/220185s000lbl.pdf. Accessed 02 Oct 2026."},{"key":"2410_CR9","unstructured":"US FDA. Jideytro (zidesamtinib): Orphan Drug designation. 2026. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=908322. Accessed 02 Oct 2026."},{"key":"2410_CR10","unstructured":"Nuvalent. Nuvalent highlights pipeline progress, reiterates key anticipated milestones and reports fourth quarter and full year 2023 financial results [media release]. 22 Feb 2024. https:\/\/investors.nuvalent.com\/2024-02-27-Nuvalent-Highlights-Pipeline-Progress,-Reiterates-Key-Anticipated-Milestones-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results."},{"key":"2410_CR11","unstructured":"GSK. GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer [media release]. 14 Sep 2026. https:\/\/www.gsk.com\/media\/z5apxwmk\/gsk-wclc-jideytro-data-press-release_final.pdf."},{"key":"2410_CR12","unstructured":"GSK. GSK completes acquisition of Nuvalent, Inc [media release].15 July 2026. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-completes-acquisition-of-nuvalent-inc\/."},{"key":"2410_CR13","doi-asserted-by":"crossref","unstructured":"Tangpeerachaikul A, Horan JC, Pelish HE. Zidesamtinib has differentiated preclinical brain penetrance and intracranial activity compared to other ROS1 inhibitors [abstract no. LB366 plus poster]. In: American Association of Cancer Research (AACR) annual meeting. 2026.","DOI":"10.1158\/1538-7445.AM2026-LB366"},{"key":"2410_CR14","doi-asserted-by":"crossref","unstructured":"Drilon A, Cho B, Lin J, et al. Pivotal ARROS-1 efficacy and safety data: zidesamtinib in TKI pre-treated patients with advanced\/metastatic ROS1+ NSCLC [abstract no. PL02.15 plus presentation]. In: 2025 World Conference on Lung Cancer. 2025.","DOI":"10.1016\/j.jtho.2025.09.018"},{"key":"2410_CR15","doi-asserted-by":"crossref","unstructured":"Liu G, Drilon AE, Besse B, et al. Zidesamtinib in patients with ROS1+NSCLC previously treated with repotrectinib or taletrectinib [abstract CT248 plus poster]. Cancer Res. 2026;86(Suppl 8):CT248.","DOI":"10.1158\/1538-7445.AM2026-CT248"},{"key":"2410_CR16","doi-asserted-by":"crossref","unstructured":"Drilon A, de Langen AJ, Besse B, et al. Zidesamtinib in TKI-naive patients with advanced\/metastatic ROS1+ NSCLC: ARROS-1 efficacy and safety data [abstract no. PL03.06 plus presentation]. In: World conference on lung cancer. 2026.","DOI":"10.1016\/j.jtho.2026.104266"},{"key":"2410_CR17","doi-asserted-by":"crossref","unstructured":"Solomon B, Popat S, Felip E, et al. Zidesamtinib efficacy and safety in patients with advanced ROS1-positive solid tumors other than NSCLC in the ARROS-1 study [abstract no. 3108 plus poster]. In: American Society of Clinical Oncology (ASCO) annual meeting. 2026.","DOI":"10.1200\/JCO.2026.44.16_suppl.3108"},{"key":"2410_CR18","unstructured":"US FDA. Jideytro (zidesamtinib): NDA approval letter. 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2026\/220185Orig1s000ltr.pdf. Accessed 02 Oct 2026."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02410-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02410-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:51:08Z","timestamp":1792731068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02410-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":18,"alternative-id":["2410"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02410-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"5 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}